Non-ST-segment Acute Coronary Syndrome
Conditions
Keywords
Fractional flow reserve, Intravascular ultrasound, Major adverse cardiovascular events, Non-ST-segment acute coronary syndrome, Percutaneous coronary intervention
Brief summary
This is an observational and prospective cohort study to examine whether the addition of IVUS plaque morphological evaluation to FFR haemodynamic assessment of non-culprit lesions in NSTEACS patients will better predict MACEs.
Detailed description
IMPACT-NSTEACS is a prospective, single-centre and dynamic observational study. The study population consists of NSTEACS patients who undergo FFR in lesions with intermediate to severe angiographic stenosis. Then, FFR-guided PCI is performed, followed by morphological assessment based on IVUS in all FFR-negative lesions (FNLs). After discharge all patients receive optimal medication treatment and are followed up clinically. On the basis of follow-up angiography, MACEs are further adjudicated as occurring at FNLs or not.
Interventions
PROCEDUREFFR-guided PCI
After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or \>90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR \>0.80 are defined as FNLs and should result in deferral of PCI.
DIAGNOSTIC_TESTIntravascular ultrasound
After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
Sponsors
Tianjin Chest Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Clinical Inclusion Criteria: 1. Moderate to high risk NSTEACS requiring invasive strategy based on current guidelines and local clinical practice. 2. Patient agrees and is able to follow all protocol procedures. Clinical
Exclusion criteria
1. STEMI or SCAD. 2. Hemodynamic instability (e.g. cardiogenic shock, refractory ventricular arrhythmias, acute and severe conduction system disease and left ventricular ejection fraction ≤30%). 3. Contraindication for FFR, PCI, IVUS and OMT (e.g. severe allergy to antiplatelet drug or contrast, significant bleed within the past 6 months, bleeding diathesis and serum creatinine ≥2.5 mg/dl). 4. PCI within 6 months or any prior CABG. 5. Anticipated life expectancy \<3 year. 6. Pregnancy 7. Unwilling or unable to provide informed consent Imaging Inclusion Criteria 1. Patients must have at least \> 1 de novo lesion in a native coronary segment with a visually estimated diameter stenosis of between 40 and 90 %. 2. Successful FFR-guided PCI performed in all major epicardial coronary arteries (including their branches): PCI for all lesions a) with 40%-90% diameter stenosis and FFR\<0.8 and b) with ≥90% diameter stenosis. 3. The FFR-negative lesions must be available for assessment of IVUS. Imaging
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence and predictors of MACEs related to FNLs | 3 years | Composite of death from cardiac causes, myocardial infarction, rehospitalization due to unstable or progressive angina and clinically-driven target lesion revascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of MACEs related to PCI-treated lesions | 3 years | Composite of death from cardiac causes, myocardial infarction, rehospitalization due to unstable or progressive angina and clinically-driven target lesion revascularization |
Other
| Measure | Time frame | Description |
|---|---|---|
| The incidence and predictors of MACEs related to FNLs | 5 years | Composite of death from cardiac causes, myocardial infarction, rehospitalization due to unstable or progressive angina and clinically-driven target lesion revascularization |
| The incidence of MACEs related to PCI-treated lesions | 5 years | Composite of death from cardiac causes, myocardial infarction, rehospitalization due to unstable or progressive angina and clinically-driven target lesion revascularization |
Countries
China
Contacts
Primary ContactJia Zhou, MD
Outcome results
None listed